loader from loading.io

Clinical Trials vs Real World Practice in Leukemia Treatment

MD Newsline

Release Date: 10/14/2025

Innovation, Access, and the Future of Cardiac Care show art Innovation, Access, and the Future of Cardiac Care

MD Newsline

In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical...

info_outline
From Awareness to Action: Cancer Prevention & Patient Empowerment show art From Awareness to Action: Cancer Prevention & Patient Empowerment

MD Newsline

In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure,...

info_outline
AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps show art AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps

MD Newsline

In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also...

info_outline
How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer show art How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer

MD Newsline

In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System’s Role in...

info_outline
Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy show art Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy

MD Newsline

In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the...

info_outline
Vitamin D, Epstein-Barr Virus, and MS Risk show art Vitamin D, Epstein-Barr Virus, and MS Risk

MD Newsline

In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the...

info_outline
Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment show art Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment

MD Newsline

In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on...

info_outline
How Ultra-Processed Food Impacts MS Progression show art How Ultra-Processed Food Impacts MS Progression

MD Newsline

In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of...

info_outline
Biomarkers in Multiple Sclerosis: Tracking Disease Progression show art Biomarkers in Multiple Sclerosis: Tracking Disease Progression

MD Newsline

In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and...

info_outline
Optic Neuritis, MS Differentials, and Modern Treatment Pathways show art Optic Neuritis, MS Differentials, and Modern Treatment Pathways

MD Newsline

In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in...

info_outline
 
More Episodes
In this episode of MD Newsline, Dr. Mark R. Litzow, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, discusses the groundbreaking findings from the ECOG-ACRIN E1910 trial and the evolving role of immunotherapy in acute lymphoblastic leukemia (ALL). He explores how real-world evidence complements clinical trials, the challenges of standardizing measurable residual disease (MRD) testing, and the future of personalized treatment strategies in hematologic malignancies.

Dr. Litzow shares deep insights into how immunotherapy has transformed survival outcomes, how clinicians can balance efficacy and neuropsychiatric side effects, and why cross-disciplinary collaboration is key to advancing oncology care.

Episode Highlights

Real-World Evidence and Clinical Practice Dr. Litzow explains the growing importance of real-world data in validating and refining clinical trial outcomes. While clinical trials have strict eligibility criteria, real-world settings introduce more patient diversity, offering valuable insights into treatment efficacy and tolerability across broader populations.

The ECOG-ACRIN E1910 Trial and Immunotherapy Advances Dr. Litzow details the E1910 trial, which compared standard chemotherapy with and without blinatumomab, an immunotherapy agent targeting CD19 and CD3. The study demonstrated a significant survival benefit—85% versus 68%— for patients receiving blinatumomab, establishing it as a new standard of care for MRD-negative ALL patients.

Integrating MRD and Genomic Profiling in Decision-Making He highlights how MRD testing and molecular risk profiling are shaping treatment pathways, enabling clinicians to better identify patients who can potentially avoid bone marrow transplantation through effective immunotherapy.

Adapting Pediatric Regimens for Adult Patients Dr. Litzow discusses the use of pediatric-inspired chemotherapy regimens in younger adults and the challenges in adapting these treatments for older or high-risk patients. He emphasizes careful monitoring for toxicities such as hepatic and neuropsychiatric effects.

Balancing Treatment Intensity and Quality of Life With immunotherapy showing strong efficacy, Dr. Litzow anticipates future strategies that reduce chemotherapy exposure, lower toxicity, and improve patient quality of life—especially for older adults or those with comorbidities.

Future Directions: AI, Cross-Specialty Collaboration, and Inflammation Research Dr. Litzow shares his optimism about artificial intelligence enhancing trial data analysis and calls for cross-disciplinary collaboration between cancer biologists and clinicians. He also emphasizes the emerging role of inflammation in cancer development, urging broader, non-linear approaches to understanding disease mechanisms.

Key Takeaway

Dr. Litzow underscores a new era in ALL treatment—where immunotherapy, real-world evidence, and molecular diagnostics intersect to personalize care, extend survival, and minimize toxicity. As clinical science evolves, the focus is shifting from intensifying chemotherapy to optimizing immune-based precision therapies that improve both outcomes and quality of life.

Resources

Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/

Connect with Dr. Mark R. Litzow: Hera


Hosted on Acast. See acast.com/privacy for more information.